Reimagining the Future of Pharma: Emerging Trends and Transformative Technologies
Dr. Sakshi Rastogi, Senior Director, NTT DATA
The pharmaceutical sector is fleetly evolving with AI-driven drug discovery, digital therapeutics, rectifiers, genomics to accelerate research and development. Emerging technologies- mRNA vaccines, wearable, personalised therapies are shortening timelines and reshaping treatments. These innovations are redefining how therapies are developed, approved, delivered tailored to the patient’s needs in a dynamic global landscape.
Digital Inflection in the Pharma Industry
This article explores cutting-edge trends shaping the future of Pharma, showcases real-world examples, applications, and presents a forward-looking view of how these innovations are redefining global healthcare for faster availability of drugs to the human beings.
The pharmaceutical industry has traditionally been seen as cautious and conservative, clinging to the high regulatory stakes, guidelines and patient safety imperatives. Triggered by the pandemic and spurred by digital ecosystems, the sector is now evolving into a tech-first landscape and pivoting towards faster, smarter, and more personalised medicine. Pharma is no longer just about the medicine, it's about platforms, managing varied data, and connected health experiences. The intersection of technology and life sciences is now a focal point, unlocking new possibilities in research and development, manufacturing, clinical trials, and patient care.
Artificial Intelligence (AI): Accelerating Research & Development and Target Discovery
With rapid advancements in artificial intelligence (AI), genomics, digital therapeutics, mRNA technology, and wearable devices, the industry is witnessing a revolution in drug discovery, product development, and its delivery to continuously ensure human safety. AI is arguably the most transformative force in the modern Pharmaceutical industry. From target identification to molecule generation and clinical trial design, AI is redefining how drugs are discovered, developed and produced. Machine learning models analyse biological data to identify novel targets, optimise molecule design, and simulate clinical outcomes. Example: Through Insilico drug discovery, companies are successfully identifying a novel drug candidate for idiopathic pulmonary fibrosis in less than 18 months, a process that typically takes over 5 years. Many biotech pioneers in precision medicine integrates multi-omics and AI to identify biomarkers and streamline oncology drug discovery. Many tools and platforms offer deep insights into cancer biology, enabling customised therapeutic approaches.
mRNA technology beyond COVID-19
By integrating AI algorithms with massive biological datasets, in the recent times, Pharma companies can predict how new compounds will behave, reduce time and cost associated with the traditional trial-and-error methods. mRNA technologies, supercharged by COVID-19 vaccine development, are now being applied to oncology, rare diseases, and autoimmune disorders. Their programmable, modular architecture enables rapid adaptation and personalisation. Its modular architecture allows rapid adaptation. Example: Moderna and BioNTech are expanding into cancer immunotherapies. AI is enhancing mRNA candidate screening and dosing strategies, driving a new generation of personalised vaccines.
mRNA’s potential lies not only in treatment, but in platform scalability and patient-specific customisation. The flexibility, speed, and scalability of mRNA platforms allow rapid iteration making them a key pillar in the future of personalised cancer vaccines, Autoimmune and infectious diseases and Enzyme replacement therapies. Many technology companies are developing platforms that harness AI-enabled multi-omics to fine-tune response prediction and boost the translational potential of mRNA-based interventions
Personalised and Precision medicines
The era of one-size-fits-all treatment is ending. With advances in the next-generation genomic sequencing and biomarker driven algorithms, precision medicine is entering mainstream care. Therapies are being tailored to each patient's genetic, environmental, and lifestyle profile. Example: Roche’s Foundation Medicine uses genomic profiling to match cancer patients with targeted therapies, often increasing survival rates and minimizing side effects. There are possible use cases of genomic-guided drug prescriptions and matching, Pharmacogenomics to avoid adverse reactions and CRISPR based gene correction, rare disease diagnostics that companies are targeting with individual treatments are reshaping how therapies are prescribed. There are precision platforms that enables contextual insights into patient variability, informing targeted interventions with fewer adverse events. This paradigm shift will enhance not only therapeutic effectiveness but in parallel minimize the adverse effects. The global precision medicine market is projected to reach $175B by 2030. – McKinsey & Co.
Digital Therapeutics (DTx) and Mobile Health
Many digital software based applications and interventions are now available to treat diseases often used in managing chronic diseases, mental health, and lifestyle disorders. Example: A regulatory approved video game treatment for paediatric ADHD (Attention-deficit hyperactivity disorder is one of the most common mental disorders affecting children), demonstrates how digital platforms can deliver therapeutic outcomes. Cognitive behavioural therapy and health management via mobile apps, Blood sugar management for diabetics and chronic disease monitoring help in managing the diseases in advance stages. DTx adoption is growing 20% YoY, especially in mental health and chronic care. As patients become more tech-savvy, DTx complements traditional therapies, offering continuous engagement and real-world effectiveness.
Decentralised Clinical Trials (DCTs), wearable’s and remote monitoring
Post COVID-19, wearables, e-consent platforms, and telemedicine are reshaping the process of performing clinical trials. DCTs minimizes the patients burden, improving geographic reach, and eliminate the participants dropout rates by 30% making the process more patient-centric through home nurse visits for remote enrolment, patient data collection, real time tracking, monitoring and assessment. Such methods are not only reducing the dropout rates, but also accelerating the patient recruitment, and increasing data diversity by involving participants across geographies and demographics empowering patients and clinicians with continuous, real-time data. Example: Few digital watches with ECG recording and apps with facial recognition technology has been used in studies to detect early atrial fibrillation prompting timely clinical interventions. These digital watches and facial recognition technology apps also enable tracking heart rate, oxygen levels, and activity data that are increasingly used in digital trials and chronic care. Emerging platforms apply connected intelligence to real-world data sources for continuous monitoring and predictive risk modelling, making trials adaptive and patient-centric. Such platforms and technologies are supporting in shifting the care from hospitals to homes. The constant flow of real-time physiological data is empowering healthcare providers to make timely, data-backed decisions. Real-world data is enriching clinical understanding and regulatory decision-making. Example: Pfizer used a fully remote model for its COVID-19 vaccine trial, collecting real-time data through digital platforms.
Supply Chain Digitization and Block Chain
Resilience in the pharmaceutical supply chain is essential, particularly in the face of global disruptions and increasing threats such as counterfeiting. The integration of digital technologies like digital twins, IoT sensors, and blockchain significantly enhances transparency, traceability, and security. However, while these technologies strengthen the supply chain, they also highlight the need for robust protection against potential digital vulnerabilities. A fully digitised pharmaceutical supply chain promotes end-to-end visibility and integrity, ensuring that every step—from production to patient delivery—is monitored and verifiable. Blockchain, in particular, plays a crucial role by creating an immutable, transparent ledger that helps detect and prevent fraud. Industry estimates suggest that blockchain-enabled pharmaceutical tracking could reduce fraud and waste by over $40 billion annually.
Sustainability and Green Chemistry
Eco-conscious manufacturing units with green chemistry principles are gaining traction and have become a boardroom priority. Sustainable practices reduce waste and carbon footprint while ensuring compliance. Example: GSK has committed to achieving net-zero carbon emissions and sustainable water use by 2030. AstraZeneca has committed to net-zero operations and green chemistry initiatives, integrating sustainability across its value chain.
Sustainability is now a top-5 KPI for 70% of global pharma CEOs. Environmental stewardship is aligning with business performance and that is the reason most of the manufacturing units are focusing on Biodegradable drug formulations, carbon-neutral facility design, Solvent recovery systems and developing Energy-efficient facilities as part of sustainability process as it is no longer an optional, it’s essential for regulatory compliance, public perception, and long-term profitability.
Regulatory Innovation: Adapting a new normal
Regulatory agencies are adopting digital tools and adaptive frameworks to keep pace with innovation. New frameworks now support faster, safer approvals of novel therapies.
Example: The FDA’s Project Orbis allows simultaneous review of oncology drugs by international regulators, accelerating global access. Another transformative approach of FDA’s Real-Time Oncology Review (RTOR) has also accelerated approval timelines without compromising safety. Global harmonization and digital regulatory submissions like eCTD, AI-aided submission reviews, RWE-based condition approvals are streamlining the path from trials and laboratory to the patients. Global harmonization is reducing time-to-market without compromising patient safety.
Future Outlook: What Lies Ahead: Pharma 2030 and the Role of Innovators
The Pharma landscape of 2030 will feature AI-powered discovery engines, genomic health passports, and digital-first therapeutics. AI-driven labs, Smart ICUs, fully virtual trials, regenerative medicine, and hyper-personalized treatments will dominate the society to provide better patient care. The organizations are working on Drug discovery with year’s long timelines shrink to the months. Many emerging platforms lead this transformation by integrating multi-omics, precision diagnostics, and AI into seamless platforms. Organizations who break silos and work on Hyper-personalized treatment regimens, In-silico trials replacing Phase I studies and Predictive public health modelling embracing data, agility, and patient-first thinking will be the front runners across the value chain.
Conclusion: From Molecule to Ecosystem
Pharmaceutical industry is shifting from a product-centric to an ecosystem-driven model. Data, technology, and personalization are the new frontiers. The convergence of science, technology, and data is revolutionizing every aspect of the pharmaceutical value chain. From faster innovation and enhanced safety to personalized treatment and real-time monitoring, the potential is limitless. To thrive in this new era, Pharma stakeholders must build cross-functional capabilities, invest in digital infrastructure, and foster a culture of innovation. The future isn’t just about better drugs; it’s about smarter systems, faster drugs availability, better healthcare and healthier lives.
Currently, many AI-powered platforms ensure a proactive, consistent, and intelligent framework for patient safety at every stage of the product journey. They exemplify how biotech and digital innovation can converge to build a smarter, more responsive healthcare system by reimagining drug development through post marketing surveillance and real world evidence with connected intelligence for real World impact where AI does not just automate tasks, it accelerates Science itself, allowing it to deliver rapid, cost effective solutions. The real-time analytics, consistency checks and predictive insights enable proactive decisions, advance interventions and continuous improvement across the entire drug life cycle for faster drug approval and patient safety. To lead this change, organisations must invest in cross-functional collaboration, agile technologies, and a culture of continuous innovation.
References:
- Insilico Medicine - AI Drug Discovery Case Studies
- FDA Real-Time Oncology Review Pilot Program
- FDA Project Orbis overview – FDA.gov
- Moderna & BioNTech mRNA pipelines – BioNTech.de & ModernaTX.com
- AstraZeneca sustainability strategy – AstraZeneca.com
Dr. Sakshi Rastogi is a Senior Director at NTT DATA. With over 23 years of experience in the Life Sciences industry, she is a seasoned physician who leads the Life Sciences Center of Excellence at a global IT company. Driven by a passion for delivering AI/ML-based solutions to global pharmaceutical clients, Dr. Rastogi aspires to be a techno-domain thought leader in patient safety and digital health transformation.
